HRP20191878T1 - Pripravci i postupci koji sadrže alkilglikozide te koji su korisni za stabilizaciju formulacija koje sadrže proteine - Google Patents
Pripravci i postupci koji sadrže alkilglikozide te koji su korisni za stabilizaciju formulacija koje sadrže proteine Download PDFInfo
- Publication number
- HRP20191878T1 HRP20191878T1 HRP20191878TT HRP20191878T HRP20191878T1 HR P20191878 T1 HRP20191878 T1 HR P20191878T1 HR P20191878T T HRP20191878T T HR P20191878TT HR P20191878 T HRP20191878 T HR P20191878T HR P20191878 T1 HRP20191878 T1 HR P20191878T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkylglycoside
- subject formulation
- glucopyranoside
- antibody
- cyclohexyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 18
- 238000009472 formulation Methods 0.000 title claims 17
- 238000000034 method Methods 0.000 title claims 14
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 239000007864 aqueous solution Substances 0.000 claims 7
- 230000003647 oxidation Effects 0.000 claims 6
- 238000007254 oxidation reaction Methods 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 230000002776 aggregation Effects 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- JVAZJLFFSJARQM-RMPHRYRLSA-N (2r,3r,4s,5s,6r)-2-hexoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-RMPHRYRLSA-N 0.000 claims 2
- JVAZJLFFSJARQM-UHFFFAOYSA-N O-n-hexyl beta-D-glucopyranoside Natural products CCCCCCOC1OC(CO)C(O)C(O)C1O JVAZJLFFSJARQM-UHFFFAOYSA-N 0.000 claims 2
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 claims 2
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- JVAZJLFFSJARQM-YBXAARCKSA-N n-Hexyl-beta-D-glucopyranoside Natural products CCCCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JVAZJLFFSJARQM-YBXAARCKSA-N 0.000 claims 2
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 claims 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- MASIZQYHVMQQKI-OIIXUNCGSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-octoxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MASIZQYHVMQQKI-OIIXUNCGSA-N 0.000 claims 1
- RHXPDNGQJSXOMW-OIIXUNCGSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6r)-6-(2-cyclohexylethoxy)-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@@H](OCCC2CCCCC2)[C@H](O)[C@H]1O RHXPDNGQJSXOMW-OIIXUNCGSA-N 0.000 claims 1
- QFAPUKLCALRPLH-UXXRCYHCSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-nonoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QFAPUKLCALRPLH-UXXRCYHCSA-N 0.000 claims 1
- -1 alkyl glycosides Chemical class 0.000 claims 1
- RVTGFZGNOSKUDA-ZNGNCRBCSA-N cyclohexyl-pentyl-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@@H](OCCCCCC2CCCCC2)[C@H](O)[C@H]1O RVTGFZGNOSKUDA-ZNGNCRBCSA-N 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- NIDYWHLDTIVRJT-UJPOAAIJSA-N heptyl-β-d-glucopyranoside Chemical compound CCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NIDYWHLDTIVRJT-UJPOAAIJSA-N 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Claims (20)
1. Predmetna formulacija, naznačena time, da se sastoji od protutijela te alkilglikozida koji ima CMC vrijednost od 1,0 mM ili veću u vodi pri 25 °C, pri čemu je alkilglikozid prisutan u predmetnoj formulaciji u koncentraciji koja je niža od CMC vrijednosti alkilglikozida u vodi pri 25 °C.
2. Predmetna formulacija patentnog zahtjeva 1, naznačena time, da se sastoji od inhibirajuće količine spomenutog alkilglikozida, koja inhibira miješanjem potaknutu agregaciju.
3. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 2, naznačena time, da se sastoji od preventivne količine spomenutog alkilglikozida koja sprečava oksidaciju.
4. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time, da je stabilna pri temperaturi od 2 do 8 °C na barem godinu dana.
5. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je stabilna pri temperaturi od 30 °C na barem mjesec dana.
6. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da nije liofilizirana te nije bila podvrgnuta prethodnoj liofilizaciji.
7. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time, da je ona rekonstituirana liofilizirana formulacija.
8. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 6, naznačena time, da je protutijelo podložno agregaciji.
9. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time, da je protutijelo podložno oksidaciji.
10. Postupak sprečavanja oksidacije protutijela prisutnog u prvoj vodenoj otopini, naznačen time, da spomenuti postupak sadrži korak dodavanja spomenutoj prvoj vodenoj otopini, preventivne količine alkilglikozida koja sprečava oksidaciju te ima CMC vrijednost od 1,0 mM ili veću u vodi pri 25 °C, pri čemu se alkilglikozid dodaje konačnoj koncentraciji koja je niža od CMC vrijednosti alkilglikozida u vodi pri 25 °C, čime se dobiva druga vodena otopina.
11. Postupak prema patentnom zahtjevu 10, naznačen time, da je spomenuta oksidacija potaknuta svjetlošću.
12. Postupak prema patentnim zahtjevima 10 ili 11, naznačen time, da je spomenuta oksidacija potaknuta svjetlošću od ostataka triptofana u spomenutom protutijelu.
13. Postupak inhibiranja miješanjem inducirane agregacije protutijela prisutnog u prvoj vodenoj otopini, naznačen time, da spomenuti postupak sadrži korak dodavanja u spomenutu prvu vodenu otopinu, inhibicijske količine alkilglikozida koja inhibira agregaciju induciranu miješanjem te koja ima CMC vrijednost od 1,0 mM ili veću u vodi pri 25 °C, pri čemu se alkilglikozid dodaje konačnoj koncentraciji koja je niža od CMC vrijednosti alkilglikozida u vodi pri 25 °C, čime se pripravlja druga vodena otopina.
14. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 9 ili postupak prema bilo kojem od patentnih zahtjeva 10 do 13, naznačeni time, da je protutijelo monoklonsko protutijelo.
15. Predmetna formulacija prema bilo kojem od patentnih zahtjeva 1 do 9 i 14 ili postupak prema bilo kojem od patentnih zahtjeva 10 do 14, naznačeni time, da je alkilglikozid odabran iz skupine koja se sastoji od n-heksil-β-D-glukopiranozida, n-heptil-β-D-glukopiranozida, n-oktil-β-D-glukopiranozida, n-nonil-β-D-glukopiranozida, n-decil-β-D-glukopiranozida, 3-cikloheksil-1-propil-β-D-glukozida, 3-cikloheksil-1-butil-β-D-glukozida, n-heksil-β-D-maltopiranozida, n-oktil-β-D-maltopiranozida, n-nonil-β-D-maltopiranozida, n-decil-β-D-maltopiranozida, cikloheksil-metil-β-D-maltozida, 2-cikloheksil-etil-β-D-maltozida, 3-cikloheksil-propil-β-D-maltozida, 4-cikloheksil-butil-β-D-maltozida te 5-cikloheksil-pentil-β-D-maltozida.
16. Predmetna formulacija ili postupak prema patentnom zahtjevu 15, naznačeni time, da je alkilglikozid n-oktil-β-D-glukopiranozid.
17. Predmetna formulacija ili postupak prema patentnom zahtjevu 15, naznačeni time, da je alkilglikozid n-decil-β-D-glukopiranozid.
18. Predmetna formulacija ili postupak prema patentnom zahtjevu 15, naznačeni time, da je alkilglikozid n-decil-β-D-maltopiranozid.
19. Predmetna formulacija ili postupak prema patentnom zahtjevu 15, naznačeni time, da je alkilglikozid n-heksil-β-D-glukopiranozid.
20. Postupak prema bilo kojem od patentnih zahtjeva 10 do 19, naznačen time, da sadrži daljnji korak liofilizacije spomenute druge vodene otopine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35810510P | 2010-06-24 | 2010-06-24 | |
PCT/US2011/041598 WO2011163458A2 (en) | 2010-06-24 | 2011-06-23 | Compositions and methods for stabilizing protein-containing formulations |
EP11730149.9A EP2585045B1 (en) | 2010-06-24 | 2011-06-23 | Compositions and methods containing alkylgycosides for stabilizing protein-containing formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191878T1 true HRP20191878T1 (hr) | 2019-12-27 |
Family
ID=44628056
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191878TT HRP20191878T1 (hr) | 2010-06-24 | 2019-10-16 | Pripravci i postupci koji sadrže alkilglikozide te koji su korisni za stabilizaciju formulacija koje sadrže proteine |
HRP20211056TT HRP20211056T1 (hr) | 2010-06-24 | 2021-07-02 | Pripravci i postupci za stabilizaciju formulacija koje sadrže proteine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211056TT HRP20211056T1 (hr) | 2010-06-24 | 2021-07-02 | Pripravci i postupci za stabilizaciju formulacija koje sadrže proteine |
Country Status (19)
Country | Link |
---|---|
US (4) | US9254321B2 (hr) |
EP (3) | EP3586826B1 (hr) |
JP (1) | JP5894154B2 (hr) |
KR (2) | KR101924653B1 (hr) |
CN (1) | CN103068367B (hr) |
AU (1) | AU2011270828B2 (hr) |
BR (1) | BR112012033002B1 (hr) |
CA (2) | CA2802756C (hr) |
ES (2) | ES2880802T3 (hr) |
HR (2) | HRP20191878T1 (hr) |
IL (2) | IL223651A (hr) |
MX (1) | MX339666B (hr) |
MY (2) | MY184736A (hr) |
NZ (1) | NZ605147A (hr) |
PL (2) | PL3586826T3 (hr) |
SG (1) | SG186783A1 (hr) |
SI (2) | SI2585045T1 (hr) |
WO (1) | WO2011163458A2 (hr) |
ZA (1) | ZA201209539B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG186783A1 (en) | 2010-06-24 | 2013-02-28 | Genentech Inc | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
MX369671B (es) * | 2013-03-13 | 2019-11-15 | Genentech Inc | Formulaciones con oxidacion reducida. |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
WO2015032981A1 (en) * | 2013-09-09 | 2015-03-12 | Lek Pharmaceuticals D.D. | Erythropoietin conjugates having oral bioavailability |
WO2015032972A1 (en) * | 2013-09-09 | 2015-03-12 | Lek Pharmaceuticals D.D. | Nanoformulation of g-csf for non-parenteral delivery |
DK3052604T3 (da) * | 2013-09-30 | 2023-06-26 | Enza Biotech Ab | Anvendelse af afspændingsmidler med alkylglykosider |
CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
KR20190027878A (ko) | 2016-07-13 | 2019-03-15 | 리폼 바이오로직스, 엘엘씨 | 치료 단백질 제제용 안정화 부형제 |
WO2019036619A1 (en) * | 2017-08-18 | 2019-02-21 | Reform Biologics, Llc | STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN |
CA3133652A1 (en) * | 2019-04-01 | 2020-10-08 | Genentech, Inc. | Compositions and methods for stabilizing protein-containing formulations |
CN114761022B (zh) * | 2019-11-29 | 2024-02-13 | 千寿制药株式会社 | 药物组合物 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
ES2039229T3 (es) * | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US5183746A (en) | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989012463A1 (en) | 1988-06-21 | 1989-12-28 | Genentech, Inc. | Method and therapeutic compositions for the treatment of myocardial infarction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
EP0602126B1 (en) | 1991-08-14 | 2003-03-05 | Genentech, Inc. | Immunoglobulin variants for specific fc epsilon receptors |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DK0674506T3 (da) | 1992-12-02 | 2001-01-08 | Alkermes Inc | Væksthormonholdige mikrosfærer med styret frigivelse |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5714338A (en) | 1993-12-10 | 1998-02-03 | Genentech, Inc. | Methods for diagnosis of allergy |
MX9602818A (es) | 1994-01-18 | 1997-06-28 | Genentech Inc | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. |
US5707622A (en) | 1994-03-03 | 1998-01-13 | Genentech, Inc. | Methods for treating ulcerative colitis |
ES2151079T3 (es) | 1994-09-09 | 2000-12-16 | Takeda Chemical Industries Ltd | Preparacion de liberacion sostenida que contiene una sal metalica de un peptido. |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
AU708756B2 (en) | 1995-06-07 | 1999-08-12 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
PT1516628E (pt) * | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
ES2183131T3 (es) | 1996-01-23 | 2003-03-16 | Genentech Inc | Anticuerpos anti-cd18 utilizados contra el ictus cerebral. |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
CA2272842C (en) | 1996-11-27 | 2012-05-15 | Genentech, Inc. | Humanized anti-cd11a antibodies |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
JP2001511653A (ja) | 1997-05-15 | 2001-08-14 | ジェネンテク,インコーポレイテッド | Apo−2レセプター |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
SI1189641T1 (sl) | 1999-06-25 | 2009-12-31 | Genentech Inc | Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2 |
DE60039448D1 (de) | 1999-10-29 | 2008-08-21 | Genentech Inc | Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
MXPA03004883A (es) | 2000-12-01 | 2004-05-04 | Battelle Memorial Institute | Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas. |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US7151164B2 (en) | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
CA2476675A1 (en) | 2001-10-17 | 2003-04-24 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
JP5416338B2 (ja) | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Cd20特異的抗体およびその使用方法 |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
AU2004263538B2 (en) | 2003-08-08 | 2009-09-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CA2611778C (en) | 2005-06-20 | 2012-11-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7390788B2 (en) * | 2005-06-23 | 2008-06-24 | Pert Candace B | Peptide pharmaceutical compositions |
US8173594B2 (en) * | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
EP2076281A4 (en) * | 2006-06-23 | 2010-03-03 | Aegis Therapeutics Inc | STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF |
WO2008012062A1 (en) * | 2006-07-24 | 2008-01-31 | Polymun Scientific Immunbiologische Forschung Gmbh | Antigenic proteoliposomes and method of manufacture |
SG186783A1 (en) * | 2010-06-24 | 2013-02-28 | Genentech Inc | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
US9813410B2 (en) | 2014-06-26 | 2017-11-07 | Rakuten, Inc. | Information processing apparatus, information processing method, and information processing program |
-
2011
- 2011-06-23 SG SG2012094223A patent/SG186783A1/en unknown
- 2011-06-23 EP EP19167191.6A patent/EP3586826B1/en active Active
- 2011-06-23 WO PCT/US2011/041598 patent/WO2011163458A2/en active Application Filing
- 2011-06-23 NZ NZ605147A patent/NZ605147A/en unknown
- 2011-06-23 EP EP21173153.4A patent/EP4008313A1/en active Pending
- 2011-06-23 MY MYPI2017000097A patent/MY184736A/en unknown
- 2011-06-23 CA CA2802756A patent/CA2802756C/en active Active
- 2011-06-23 CN CN201180040661.1A patent/CN103068367B/zh active Active
- 2011-06-23 CA CA3111727A patent/CA3111727C/en active Active
- 2011-06-23 SI SI201131803T patent/SI2585045T1/sl unknown
- 2011-06-23 ES ES19167191T patent/ES2880802T3/es active Active
- 2011-06-23 PL PL19167191T patent/PL3586826T3/pl unknown
- 2011-06-23 KR KR1020137001772A patent/KR101924653B1/ko active IP Right Grant
- 2011-06-23 AU AU2011270828A patent/AU2011270828B2/en active Active
- 2011-06-23 JP JP2013516765A patent/JP5894154B2/ja active Active
- 2011-06-23 EP EP11730149.9A patent/EP2585045B1/en active Active
- 2011-06-23 PL PL11730149T patent/PL2585045T3/pl unknown
- 2011-06-23 ES ES11730149T patent/ES2751381T3/es active Active
- 2011-06-23 MX MX2012014862A patent/MX339666B/es active IP Right Grant
- 2011-06-23 MY MYPI2012005503A patent/MY161390A/en unknown
- 2011-06-23 SI SI201131987T patent/SI3586826T1/sl unknown
- 2011-06-23 KR KR1020187034269A patent/KR102058307B1/ko active IP Right Grant
- 2011-06-23 BR BR112012033002-0A patent/BR112012033002B1/pt active IP Right Grant
-
2012
- 2012-12-14 ZA ZA2012/09539A patent/ZA201209539B/en unknown
- 2012-12-16 IL IL223651A patent/IL223651A/en active IP Right Grant
- 2012-12-20 US US13/722,559 patent/US9254321B2/en active Active
-
2015
- 2015-12-11 US US14/966,363 patent/US10188735B2/en active Active
-
2017
- 2017-09-06 IL IL254354A patent/IL254354B/en active IP Right Grant
-
2018
- 2018-12-10 US US16/215,003 patent/US11103584B2/en active Active
-
2019
- 2019-10-16 HR HRP20191878TT patent/HRP20191878T1/hr unknown
-
2021
- 2021-07-02 HR HRP20211056TT patent/HRP20211056T1/hr unknown
- 2021-07-27 US US17/386,385 patent/US11938189B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191878T1 (hr) | Pripravci i postupci koji sadrže alkilglikozide te koji su korisni za stabilizaciju formulacija koje sadrže proteine | |
HRP20200793T1 (hr) | Liječenje raka | |
HRP20180158T1 (hr) | Spojevi biarilamida kao inhibitori kinaze | |
MX2019010221A (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida aprocitentan. | |
HRP20200134T1 (hr) | Silika hidrogel kompozit | |
EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
JP2009531457A5 (hr) | ||
MX362792B (es) | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados. | |
MY150613A (en) | Stabilizer and vaccine composition comprising one or more live attenuated flaviviruses | |
EA201791261A1 (ru) | 1,3-тиазол-2-ил замещенные бензамиды | |
UA111167C2 (uk) | Пестицидні композиції мезорозмірних частинок з підсиленою дією | |
MX2017010699A (es) | Composicion para el cuidado de telas que comprende poliolesteres insaturados metatesizados. | |
MX340732B (es) | Composicion secuestrante de calcio. | |
MX370168B (es) | Composiciones para el cuidado bucal. | |
AR084318A1 (es) | Composicion que comprende particulas de insecticida-cera | |
MY163134A (en) | Composition containing riboflavin and sesamin-class compounds | |
PH12016501932A1 (en) | Amido-substituted azole compounds | |
EA202092926A2 (ru) | Лиофилизированные составы, содержащие фактор ix | |
EA201591011A1 (ru) | Композиции для ухода за полостью рта | |
GEP20237539B (en) | Formulations of dengue virus vaccine compositions | |
JP2019180364A5 (ja) | 持続的注意力改善用食品組成物、持続的注意力改善剤、及び、これらの製造方法 | |
BRPI0709361B8 (pt) | composição, métodos para a preparação de um alimento e método para o tratamento de listeria | |
AR078855A1 (es) | Composiciones y metodos para mejorar las pestanas | |
JP6755614B2 (ja) | 塩味増強剤 | |
HRP20240090T1 (hr) | Kompozicija za prevenciju i/ili liječenje simptoma alergije |